Article
[A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma].
Zhonghua zhong liu za zhi [Chinese journal of oncology] - 23 Feb 2018
Chen W Q, Li P, Wang Q, Zhang Y J, Li H Y, Jin X T, Yan S, Kou G F, Cai S L, Liu G
Abstract excerpt
Objective: To evaluate the feasibility, efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs) for neoadjuvant therapy. Methods: Eighty-six patients with stage ⅢA EGFR-mutant lung adenocarcinoma were assigned to 2 groups (n=43 in each group) according to the random number table method: neoadjuvant targeted therapy group (single oral dose of erlotinib 150 mg per day, for 9...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.